Showing 2741-2750 of 4166 results for "".
- New Study Shows Zepto Precision Pulse Capsulotomy Safeguards Endothelial Cells as Effectively as Manual Capsulorhexishttps://modernod.com/news/new-study-shows-zepto-precision-pulse-capsulotomy-safeguards-endothelial-cells-as-effectively-as-manual-capsulorhexis/2481724/Centricity Vision announced that a
- Centricity: Study Finds Zepto Precision Pulse Capsulotomy Offers Advantages Over Manual Capsulorhexis in Treating White Cataractshttps://modernod.com/news/centricy-study-finds-zepto-precision-pulse-capsulotomy-offers-advantages-over-manual-capsulorhexis-in-treating-white-cataracts/2481513/Centricity Vision announced that a
- New Study Shows Eylea HD with Extended 12- or 16-Week Dosing Demonstrated Noninferior Vision Gains to Standard of Care Eyleahttps://modernod.com/news/lancet-study-eylea-hd-with-extended-12-or-16-week-dosing-demonstrated-noninferior-vision-gains-to-standard-of-care-eylea/2482151/Regeneron announced The Lancet published 1-year results from the pivotal PULSAR and
- Two-Year Results for Aflibercept 8 mg from PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in DMEhttps://modernod.com/news/two-year-results-for-aflibercept-8-mg-from-photon-trial-demonstrate-durable-vision-gains-at-extended-dosing-intervals-in-dme/2481696/Regeneron released on Tuesday topline, 2-year (96 weeks) data for aflibercept 8 mg from the PHOTON trial in patients with diabetic macular edema (DME). During the trial, aflibercept 8 mg patients were initially randomized to either 12- or 16-week dosing intervals (after three initial monthly
- Conference and Exhibit Hall Registration Now Open for Vision Expo East 2023 Taking Place March 16-19 in New York Cityhttps://modernod.com/news/conference-and-exhibit-hall-registration-now-open-for-vision-expo-east-2023-taking-place-march-16-19-in-new-york-city/2481282/Conference and Exhibit Hall Registration opens today for
- Treehouse Eyes Partners with J&J Vision to Deliver Treatment Innovation for Myopia Management: Acuvue Abiliti Overnight Therapeutic Lenseshttps://modernod.com/news/treehouse-eyes-partners-with-jj-vision-to-deliver-treatment-innovation-for-myopia-management-acuvue-abiliti-overnight-therapeutic-lenses/2480497/Treehouse Eyes, a health care business dedicated exclusively to treating myopic chi
- Late-Breaking 12-Month Data of Investigational RPGR Gene Therapy Shows Statistically Significant and Continued Vision Improvement in Patients with XLRPhttps://modernod.com/news/late-breaking-12-month-data-of-investigational-rpgr-gene-therapy-shows-statistically-significant-and-continued-vision-improvement-in-patients-with-xlrp/2478557/The Janssen Pharmaceutical Companies of Johnson & Johnson announced new 12-month data from the ongoing phase 1/2 trial (
- Interim 6-Month Data of RPGR Gene Therapy Shows Significant Vision Improvement in Patients Living with X-Linked Retinitis Pigmentosahttps://modernod.com/news/interim-6-month-data-of-rpgr-gene-therapy-shows-significant-vision-improvement-in-patients-living-with-x-linked-retinitis-pigmentosa/2478036/The Janssen Pharmaceutical Companies of Johnson & Johnson announced 6-month data from the ongoing phase 1/2 trial of its investigational gene therapy for the treatment of inherited retinal disease X-linked retinitis pigmentosa (XLRP). The interim data showed that low and intermediate doses of
- Oculus and Myopia Profile Aim to Increase Knowledge on Myopiahttps://modernod.com/news/oculus-and-myopia-profile-aim-to-increase-knowledge-on-myopia/2478860/Myopia Profile and Oculus have commenced a partnership to increase ECP knowledge and clinical confidence in measurement and interpretation of axial length in myopia. Specific educational content, research summaries and case studies will be developed, to be housed on MyopiaProfile.com and shared a
- Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trialhttps://modernod.com/news/nicox-announces-last-patient-completes-the-ncx-470-denali-phase-3-clinical-trial/2482865/Nicox SA announced the completion of patient treatment and follow-up in the Denali phase 3 clinical trial for NCX 470, its lead candidate for the treatment of open-angle glaucoma and ocular hypertension. In total, 696 p